2025 H2 -tulosraportti
182 päivää sitten
‧38 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. | Tänään |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sitten · MuokattuShip ahoy ⛵ Our ship has no revenue this quarter, so numbers tomorrow everyone knows will be and are terribly red..It's the guidance and fabrikk news that can lift the share price..But some took short-term gains on a 50 % increase. That's natural. And all stocks that do well get a pullback..So time will show 💰💰 Think ahead 2 years and the price is kr 40. No one knows..
Tomorrow will show if there is any knowledge behind these assessments..I hope so ☝️🤝
·5 t sittenHmmm what does one do tomorrow, place some sell orders to secure, or sit quietly in the boat as one usually does 🏊♂️
I'm staying in. If there should be a dip, the case is so solid anyway that I will willingly join that ride down. When 2027 approaches, I will anyway believe that we are above today's price. Good journey!
·6 t sittenThor Medical ASA (TRMED) will present its half-year results for H1 2026 tomorrow, Friday, August 28, 2026. The report will be published at 07:00 CEST, followed by a presentation at 08:00 CEST at Sjølyst Møtesenter in Oslo (with webcast). What's happening in the background (important recent milestones) July 31, 2026: AlphaOne (first commercial production facility at Herøya) started commercial production of lead-212 (Pb-212) and the precursors thorium-228 (Th-228) and radium-224 (Ra-224). The facility was delivered on time and on budget. August 5, 2026: First customer delivery (high-purity Thorium-228) from AlphaOne completed. August 25, 2026: Strengthening of management – CFO/COO Brede Ellingsæter transitions to a dedicated COO role (focus on operations and commercial scaling); recruitment of a new CFO is underway. Official opening of AlphaOne by Prime Minister Jonas Gahr Støre planned for September 9, 2026. The company is in an early commercial phase. In 2025, they had very limited revenues (first deliveries), higher operating costs related to the construction of AlphaOne and organizational building, and solid cash reserves (approx. NOK 181 million at the end of 2025) plus loan facilities. Order backlog was previously around NOK 850 million via multi-year agreements. The goal has been increasing revenues from the second half of 2026 and positive cash flow towards the end of 2027. What can be expected in the H1 2026 figures? Since AlphaOne first entered commercial production towards the end of July, H1 2026 (January–June) will probably still show: Very low or limited revenues (mainly from pilot/early deliveries). Continued operating loss/EBITDA loss, driven by investments, staffing, and start-up costs. Focus on the balance sheet: cash reserves, capital expenditure on AlphaOne, and financing status (the company has previously communicated that AlphaOne is fully financed through ramp-up). The presentation will likely place greater emphasis on operational and commercial updates than the pure H1 figures: Status of production ramp-up in AlphaOne (capacity will gradually increase towards approx. 21,000 patient dose equivalents after three years). Deliveries and order backlog. Market outlook for alpha-emitters in radioligand therapy (strong growth expected). Roadmap towards higher volumes in H2 2026 and positive cash flow in 2027. Any new agreements, partnerships, or capacity plans. In short: Expect more "milestone-update" and progress in commercialization than large revenue increases in the H1 figures. The market will closely monitor the ramp-up pace, deliveries, and any updated guidance. Report and presentation will be published on thormedical.com at 07:00.
·9 t sittenPb-212 does not only kill the cancer cell. In preclinical models against melanoma, Perspective Therapeutics' VMT01 also triggered an immune response, and acted together with checkpoint inhibitors. They believe Pb-212 is well suited in combination because the radiation acts quickly. VMT01 is in phase 1/2a against melanoma, both alone and together with nivolumab. New clinical data is expected late in 2026. The more data that shows that the isotope can be used together with immunotherapy, the greater the demand for Th-228 and Pb-212. https://www.linkedin.com/posts/perspective-therapeutics_catx-targetedalphatherapy-oncology-activity-7498741385475469312-7iBI?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
182 päivää sitten
‧38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sitten · MuokattuShip ahoy ⛵ Our ship has no revenue this quarter, so numbers tomorrow everyone knows will be and are terribly red..It's the guidance and fabrikk news that can lift the share price..But some took short-term gains on a 50 % increase. That's natural. And all stocks that do well get a pullback..So time will show 💰💰 Think ahead 2 years and the price is kr 40. No one knows..Tomorrow will show if there is any knowledge behind these assessments..I hope so ☝️🤝
- ·5 t sittenHmmm what does one do tomorrow, place some sell orders to secure, or sit quietly in the boat as one usually does 🏊♂️I'm staying in. If there should be a dip, the case is so solid anyway that I will willingly join that ride down. When 2027 approaches, I will anyway believe that we are above today's price. Good journey!
- ·6 t sittenThor Medical ASA (TRMED) will present its half-year results for H1 2026 tomorrow, Friday, August 28, 2026. The report will be published at 07:00 CEST, followed by a presentation at 08:00 CEST at Sjølyst Møtesenter in Oslo (with webcast). What's happening in the background (important recent milestones) July 31, 2026: AlphaOne (first commercial production facility at Herøya) started commercial production of lead-212 (Pb-212) and the precursors thorium-228 (Th-228) and radium-224 (Ra-224). The facility was delivered on time and on budget. August 5, 2026: First customer delivery (high-purity Thorium-228) from AlphaOne completed. August 25, 2026: Strengthening of management – CFO/COO Brede Ellingsæter transitions to a dedicated COO role (focus on operations and commercial scaling); recruitment of a new CFO is underway. Official opening of AlphaOne by Prime Minister Jonas Gahr Støre planned for September 9, 2026. The company is in an early commercial phase. In 2025, they had very limited revenues (first deliveries), higher operating costs related to the construction of AlphaOne and organizational building, and solid cash reserves (approx. NOK 181 million at the end of 2025) plus loan facilities. Order backlog was previously around NOK 850 million via multi-year agreements. The goal has been increasing revenues from the second half of 2026 and positive cash flow towards the end of 2027. What can be expected in the H1 2026 figures? Since AlphaOne first entered commercial production towards the end of July, H1 2026 (January–June) will probably still show: Very low or limited revenues (mainly from pilot/early deliveries). Continued operating loss/EBITDA loss, driven by investments, staffing, and start-up costs. Focus on the balance sheet: cash reserves, capital expenditure on AlphaOne, and financing status (the company has previously communicated that AlphaOne is fully financed through ramp-up). The presentation will likely place greater emphasis on operational and commercial updates than the pure H1 figures: Status of production ramp-up in AlphaOne (capacity will gradually increase towards approx. 21,000 patient dose equivalents after three years). Deliveries and order backlog. Market outlook for alpha-emitters in radioligand therapy (strong growth expected). Roadmap towards higher volumes in H2 2026 and positive cash flow in 2027. Any new agreements, partnerships, or capacity plans. In short: Expect more "milestone-update" and progress in commercialization than large revenue increases in the H1 figures. The market will closely monitor the ramp-up pace, deliveries, and any updated guidance. Report and presentation will be published on thormedical.com at 07:00.
- ·9 t sittenPb-212 does not only kill the cancer cell. In preclinical models against melanoma, Perspective Therapeutics' VMT01 also triggered an immune response, and acted together with checkpoint inhibitors. They believe Pb-212 is well suited in combination because the radiation acts quickly. VMT01 is in phase 1/2a against melanoma, both alone and together with nivolumab. New clinical data is expected late in 2026. The more data that shows that the isotope can be used together with immunotherapy, the greater the demand for Th-228 and Pb-212. https://www.linkedin.com/posts/perspective-therapeutics_catx-targetedalphatherapy-oncology-activity-7498741385475469312-7iBI?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. | Tänään |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
2025 H2 -tulosraportti
182 päivää sitten
‧38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. | Tänään |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sitten · MuokattuShip ahoy ⛵ Our ship has no revenue this quarter, so numbers tomorrow everyone knows will be and are terribly red..It's the guidance and fabrikk news that can lift the share price..But some took short-term gains on a 50 % increase. That's natural. And all stocks that do well get a pullback..So time will show 💰💰 Think ahead 2 years and the price is kr 40. No one knows..Tomorrow will show if there is any knowledge behind these assessments..I hope so ☝️🤝
- ·5 t sittenHmmm what does one do tomorrow, place some sell orders to secure, or sit quietly in the boat as one usually does 🏊♂️I'm staying in. If there should be a dip, the case is so solid anyway that I will willingly join that ride down. When 2027 approaches, I will anyway believe that we are above today's price. Good journey!
- ·6 t sittenThor Medical ASA (TRMED) will present its half-year results for H1 2026 tomorrow, Friday, August 28, 2026. The report will be published at 07:00 CEST, followed by a presentation at 08:00 CEST at Sjølyst Møtesenter in Oslo (with webcast). What's happening in the background (important recent milestones) July 31, 2026: AlphaOne (first commercial production facility at Herøya) started commercial production of lead-212 (Pb-212) and the precursors thorium-228 (Th-228) and radium-224 (Ra-224). The facility was delivered on time and on budget. August 5, 2026: First customer delivery (high-purity Thorium-228) from AlphaOne completed. August 25, 2026: Strengthening of management – CFO/COO Brede Ellingsæter transitions to a dedicated COO role (focus on operations and commercial scaling); recruitment of a new CFO is underway. Official opening of AlphaOne by Prime Minister Jonas Gahr Støre planned for September 9, 2026. The company is in an early commercial phase. In 2025, they had very limited revenues (first deliveries), higher operating costs related to the construction of AlphaOne and organizational building, and solid cash reserves (approx. NOK 181 million at the end of 2025) plus loan facilities. Order backlog was previously around NOK 850 million via multi-year agreements. The goal has been increasing revenues from the second half of 2026 and positive cash flow towards the end of 2027. What can be expected in the H1 2026 figures? Since AlphaOne first entered commercial production towards the end of July, H1 2026 (January–June) will probably still show: Very low or limited revenues (mainly from pilot/early deliveries). Continued operating loss/EBITDA loss, driven by investments, staffing, and start-up costs. Focus on the balance sheet: cash reserves, capital expenditure on AlphaOne, and financing status (the company has previously communicated that AlphaOne is fully financed through ramp-up). The presentation will likely place greater emphasis on operational and commercial updates than the pure H1 figures: Status of production ramp-up in AlphaOne (capacity will gradually increase towards approx. 21,000 patient dose equivalents after three years). Deliveries and order backlog. Market outlook for alpha-emitters in radioligand therapy (strong growth expected). Roadmap towards higher volumes in H2 2026 and positive cash flow in 2027. Any new agreements, partnerships, or capacity plans. In short: Expect more "milestone-update" and progress in commercialization than large revenue increases in the H1 figures. The market will closely monitor the ramp-up pace, deliveries, and any updated guidance. Report and presentation will be published on thormedical.com at 07:00.
- ·9 t sittenPb-212 does not only kill the cancer cell. In preclinical models against melanoma, Perspective Therapeutics' VMT01 also triggered an immune response, and acted together with checkpoint inhibitors. They believe Pb-212 is well suited in combination because the radiation acts quickly. VMT01 is in phase 1/2a against melanoma, both alone and together with nivolumab. New clinical data is expected late in 2026. The more data that shows that the isotope can be used together with immunotherapy, the greater the demand for Th-228 and Pb-212. https://www.linkedin.com/posts/perspective-therapeutics_catx-targetedalphatherapy-oncology-activity-7498741385475469312-7iBI?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt